×
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   289.59 (+0.92%)
AAPL   143.32 (+1.24%)
MSFT   266.84 (+1.52%)
META   169.40 (+0.72%)
GOOGL   2,283.79 (+0.82%)
AMZN   114.88 (+1.22%)
TSLA   694.58 (-0.66%)
NVDA   151.93 (+1.53%)
NIO   20.69 (-6.72%)
BABA   118.78 (-1.12%)
AMD   75.62 (+0.56%)
MU   57.68 (+1.67%)
CGC   2.67 (-1.48%)
T   21.19 (+0.09%)
GE   61.92 (-0.18%)
F   11.17 (-0.27%)
DIS   96.54 (-0.66%)
AMC   12.56 (-1.72%)
PFE   52.34 (+1.36%)
PYPL   73.56 (-1.13%)
NFLX   184.79 (-0.59%)
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   289.59 (+0.92%)
AAPL   143.32 (+1.24%)
MSFT   266.84 (+1.52%)
META   169.40 (+0.72%)
GOOGL   2,283.79 (+0.82%)
AMZN   114.88 (+1.22%)
TSLA   694.58 (-0.66%)
NVDA   151.93 (+1.53%)
NIO   20.69 (-6.72%)
BABA   118.78 (-1.12%)
AMD   75.62 (+0.56%)
MU   57.68 (+1.67%)
CGC   2.67 (-1.48%)
T   21.19 (+0.09%)
GE   61.92 (-0.18%)
F   11.17 (-0.27%)
DIS   96.54 (-0.66%)
AMC   12.56 (-1.72%)
PFE   52.34 (+1.36%)
PYPL   73.56 (-1.13%)
NFLX   184.79 (-0.59%)
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   289.59 (+0.92%)
AAPL   143.32 (+1.24%)
MSFT   266.84 (+1.52%)
META   169.40 (+0.72%)
GOOGL   2,283.79 (+0.82%)
AMZN   114.88 (+1.22%)
TSLA   694.58 (-0.66%)
NVDA   151.93 (+1.53%)
NIO   20.69 (-6.72%)
BABA   118.78 (-1.12%)
AMD   75.62 (+0.56%)
MU   57.68 (+1.67%)
CGC   2.67 (-1.48%)
T   21.19 (+0.09%)
GE   61.92 (-0.18%)
F   11.17 (-0.27%)
DIS   96.54 (-0.66%)
AMC   12.56 (-1.72%)
PFE   52.34 (+1.36%)
PYPL   73.56 (-1.13%)
NFLX   184.79 (-0.59%)
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   289.59 (+0.92%)
AAPL   143.32 (+1.24%)
MSFT   266.84 (+1.52%)
META   169.40 (+0.72%)
GOOGL   2,283.79 (+0.82%)
AMZN   114.88 (+1.22%)
TSLA   694.58 (-0.66%)
NVDA   151.93 (+1.53%)
NIO   20.69 (-6.72%)
BABA   118.78 (-1.12%)
AMD   75.62 (+0.56%)
MU   57.68 (+1.67%)
CGC   2.67 (-1.48%)
T   21.19 (+0.09%)
GE   61.92 (-0.18%)
F   11.17 (-0.27%)
DIS   96.54 (-0.66%)
AMC   12.56 (-1.72%)
PFE   52.34 (+1.36%)
PYPL   73.56 (-1.13%)
NFLX   184.79 (-0.59%)
NASDAQ:ELDN

Eledon Pharmaceuticals Stock Forecast, Price & News

$2.97
+0.09 (+3.13%)
(As of 07/6/2022 02:39 PM ET)
Add
Compare
Today's Range
$2.90
$3.07
50-Day Range
$2.34
$3.80
52-Week Range
$2.27
$8.49
Volume
827 shs
Average Volume
85,481 shs
Market Capitalization
$40.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Eledon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
626.1% Upside
$22.00 Price Target
Short Interest
Healthy
0.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Eledon Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.57) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.10 out of 5 stars

Medical Sector

387th out of 1,426 stocks

Pharmaceutical Preparations Industry

183rd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Eledon Pharmaceuticals logo

About Eledon Pharmaceuticals (NASDAQ:ELDN) Stock

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock News Headlines

Eledon Pharmaceuticals Inc - Stock News
A Preview Of Eledon Pharmaceuticals's Earnings
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
12
Year Founded
N/A

Company Calendar

Last Earnings
11/11/2021
Today
7/06/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+640.7%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-34,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.46 per share

Miscellaneous

Free Float
11,859,000
Market Cap
$40.87 million
Optionable
Not Optionable
Beta
1.98














Eledon Pharmaceuticals Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Eledon Pharmaceuticals stock.
View analyst ratings for Eledon Pharmaceuticals
or view top-rated stocks.

What is Eledon Pharmaceuticals' stock price forecast for 2022?

4 analysts have issued 1-year price objectives for Eledon Pharmaceuticals' stock. Their ELDN stock forecasts range from $15.00 to $26.00. On average, they expect Eledon Pharmaceuticals' share price to reach $22.00 in the next year. This suggests a possible upside of 640.7% from the stock's current price.
View analysts' price targets for Eledon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Eledon Pharmaceuticals' stock performed in 2022?

Eledon Pharmaceuticals' stock was trading at $4.41 at the start of the year. Since then, ELDN stock has decreased by 32.7% and is now trading at $2.97.
View the best growth stocks for 2022 here
.

When is Eledon Pharmaceuticals' next earnings date?

Eledon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Eledon Pharmaceuticals
.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.01. During the same quarter last year, the company earned ($3.91) earnings per share.
View Eledon Pharmaceuticals' earnings history
.

Who are Eledon Pharmaceuticals' key executives?

Eledon Pharmaceuticals' management team includes the following people:
  • Dr. David-Alexandre C. Gros M.D., Ph.D., CEO & Non Independent Director (Age 50, Pay $604.1k) (LinkedIn Profile)
  • Dr. Steven N. Perrin Ph.D., Pres, Chief Scientific Officer & Non Independent Director (Age 56)
  • Mr. Paul Sean Little, CFO & Principal Accounting Officer (Age 57, Pay $408.93k)
  • Mr. Bryan E. Smith J.D., Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 42, Pay $377.14k)
  • Mr. John Herberger, VP of Technical Operations
  • Mr. Gregory J. Flesher, Consultant (Age 52)
  • Dr. Jeffrey D. Bornstein, Chief Medical Officer
  • Dr. David Hovland Ph.D., Chief Regulatory Officer

What is Eledon Pharmaceuticals' stock symbol?

Eledon Pharmaceuticals trades on the NASDAQ under the ticker symbol "ELDN."

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eledon Pharmaceuticals' stock price today?

One share of ELDN stock can currently be purchased for approximately $2.97.

How much money does Eledon Pharmaceuticals make?

Eledon Pharmaceuticals (NASDAQ:ELDN) has a market capitalization of $40.87 million. The company earns $-34,510,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis.

How many employees does Eledon Pharmaceuticals have?

Eledon Pharmaceuticals employs 12 workers across the globe.

How can I contact Eledon Pharmaceuticals?

Eledon Pharmaceuticals' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The official website for Eledon Pharmaceuticals is novustherapeutics.com. The company can be reached via phone at (949) 238-8090 or via email at investors@novustherapeutics.com.

This page (NASDAQ:ELDN) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.